loading

Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten

pulisher
Feb 06, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - Investing.com

Feb 06, 2025
pulisher
Feb 06, 2025

Tango Therapeutics executive sells shares worth $43,865 - Investing.com

Feb 06, 2025
pulisher
Feb 06, 2025

Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News

Feb 06, 2025
pulisher
Feb 06, 2025

TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

Exclusive BAC Article: Tango Therapeutics; 2nd Half Of 2024 MTAP-Deletion Tumor Data TNG-908/TNG-462, TNG-260 Phase 1/2 Trial Advancement And Catalysts (NASDAQ:TNGX) - Seeking Alpha

Feb 05, 2025
pulisher
Feb 05, 2025

TNGX (Tango Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Tango Therapeutics Inc’s Market Journey: Closing Strong at 3.04, Up 4.47 - The Dwinnex

Feb 05, 2025
pulisher
Feb 01, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $13.14 Average Price Target from Analysts - MarketBeat

Feb 01, 2025
pulisher
Jan 30, 2025

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - The Manila Times

Jan 30, 2025
pulisher
Jan 30, 2025

Precision Cancer Medicine Pioneer Tango Therapeutics Takes Center Stage at Elite Biotech Conference - StockTitan

Jan 30, 2025
pulisher
Jan 29, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jan 29, 2025
pulisher
Jan 23, 2025

Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Estimates TNGX FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Forecasts TNGX FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 15, 2025

Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower - Simply Wall St

Jan 15, 2025
pulisher
Jan 15, 2025

Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Tango Therapeutics Highlights Breakthroughs in Cancer Treatment - TipRanks

Jan 13, 2025
pulisher
Jan 08, 2025

Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 08, 2025
pulisher
Jan 04, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Buy" by Analysts - MarketBeat

Jan 04, 2025
pulisher
Jan 03, 2025

Franklin Resources Inc. Has $126,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 03, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Has $10.54 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

Barclays PLC Raises Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 31, 2024
pulisher
Dec 24, 2024

State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 24, 2024
pulisher
Dec 24, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by State Street Corp - MarketBeat

Dec 24, 2024
pulisher
Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $580,000 Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 21, 2024
pulisher
Dec 17, 2024

The Manufacturers Life Insurance Company Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 17, 2024
pulisher
Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com India

Dec 14, 2024
pulisher
Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa

Dec 14, 2024
pulisher
Dec 13, 2024

TNGX Stock Hits 52-Week Low at $2.7 Amid Market Challenges - Investing.com UK

Dec 13, 2024
pulisher
Dec 10, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Dec 10, 2024
pulisher
Dec 07, 2024

Cantor Fitzgerald Reaffirms Overweight Rating for Tango Therapeutics (NASDAQ:TNGX) - Defense World

Dec 07, 2024
pulisher
Dec 05, 2024

Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register

Dec 05, 2024
pulisher
Dec 05, 2024

Unveiling 5 Analyst Insights On Tango Therapeutics - Benzinga

Dec 05, 2024
pulisher
Dec 05, 2024

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth? - Simply Wall St

Dec 05, 2024
pulisher
Dec 03, 2024

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Dec 03, 2024
pulisher
Nov 29, 2024

Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 21.7% - MarketBeat

Nov 29, 2024
pulisher
Nov 27, 2024

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire

Nov 27, 2024
pulisher
Nov 23, 2024

Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey

Nov 23, 2024
pulisher
Nov 19, 2024

Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock By Investing.com - Investing.com Canada

Nov 19, 2024
pulisher
Nov 18, 2024

Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com

Nov 18, 2024
pulisher
Nov 17, 2024

Trv Gp Iv LLC Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat

Nov 14, 2024
$80.78
price down icon 0.82%
$20.67
price down icon 0.53%
$353.75
price down icon 0.12%
$5.04
price down icon 2.14%
biotechnology ONC
$228.87
price up icon 0.53%
$119.94
price down icon 1.99%
Kapitalisierung:     |  Volumen (24h):